Form D · Biotechnology

MOLECULARMD CORP.

Portland, OR · CIK 0001542181

Offering snapshot reported Feb 10, 2017 · SEC filing

Reported sold
$2.07M
Offering amount: $2.07M
Investors reported
7
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jan 31, 2017
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Feb 10, 2017Initial$2,070,300No comparison7SEC filing
Jul 18, 2016Initial$500,000No comparison6SEC filing
May 20, 2013Initial$2,500,000No comparison4SEC filing
Apr 5, 2012Amendment$8,000,000$0vs Feb 15, 20126SEC filing
Feb 15, 2012Initial$8,000,000No comparison4SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-280459

Source: Form D, filed Feb 10, 2017. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Richard Brandewie Director
Cheryl Calhoun Executive
Ryan Dunlap Executive
Fritz Eibel Director
Frederick Eibel Executive
Chad Galderisi Executive
Drew Graham Director
Peter Maag Director
Matthew Rice Director
Sheridan G. Snyder Director
Cindy Spittle Executive
Teri Swift Executive
Stephane Wong Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
1341 Sw Custer Drive
Portland, OR, 97219